What are primary cutaneous B-cell lymphomas?
Primary cutaneous B-cell lymphomas (PCBCL) are lymphomas that start in the skin and stay there at the time of diagnosis. They develop from B lymphocytes, the white blood cells that normally make antibodies.
“Primary cutaneous” means the skin is the first and only place affected. This is different from a lymphoma that starts in the lymph nodes and later spreads to the skin, which is treated in another way.
About one in four lymphomas that start in the skin are B-cell types. Most of the rest are T-cell lymphomas, such as mycosis fungoides.
There are three main types. Two of them, marginal zone and follicle centre lymphoma, grow slowly and almost never shorten life. The third, diffuse large B-cell lymphoma, leg type, is more aggressive and needs treatment like a lymphoma elsewhere in the body.
They usually show up as pink, red or purple lumps or plaques on the skin. Most people feel well otherwise.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Non-Hodgkin lymphoma of B cells, starting in the skin |
| How common | About 20-25% of primary skin lymphomas; a few cases per million people each year |
| Typical age | Indolent types: mostly 40-60; leg type: mostly over 70 |
| Main types | Marginal zone, follicle centre, and diffuse large B-cell lymphoma, leg type |
| Main sites | Trunk and arms (marginal zone), head, scalp and back (follicle centre), lower legs (leg type) |
| Spread | Rare in indolent types; leg type spreads to nodes and organs in about a third or more |
| Main treatments | Radiotherapy, surgery, injections into the lesion, rituximab, R-CHOP chemotherapy for leg type |
| Outlook | Indolent types: over 95% alive at 5 years from the lymphoma; leg type: about 50-60% |
2. Types of primary cutaneous B-cell lymphoma
The classification comes from the WHO-EORTC system for skin lymphomas, updated in 2018, and the WHO 2022 classification.
| Type | Who and where | Behaviour |
|---|---|---|
| Primary cutaneous marginal zone lymphoma (PCMZL) | Young and middle-aged adults; arms and trunk | Very slow; skin lesions often come back, but spread beyond the skin is rare. The International Consensus Classification calls it a “lymphoproliferative disorder” |
| Primary cutaneous follicle centre lymphoma (PCFCL) | Middle-aged adults; head, scalp, forehead and back | Slow-growing; excellent outlook, even with large lesions |
| Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) | Older adults, more often women; usually one or both lower legs | Aggressive; can spread to lymph nodes and other organs |
| Rarer types | EBV-positive mucocutaneous ulcer, intravascular large B-cell lymphoma | Very uncommon; managed by specialists |
3. Causes and risk factors
In most people there is no clear cause.
| Factor | Notes |
|---|---|
| Chronic immune stimulation | Marginal zone lymphoma may follow long-standing immune activation in the skin |
| Borrelia infection | In parts of Europe, some marginal zone lymphomas have been linked to Borrelia burgdorferi, the bacterium that causes Lyme disease |
| Weakened immune system | Immune-suppressing drugs or HIV slightly raise the risk, mainly of EBV-related lesions |
| Gene changes (leg type) | MYD88 L265P and CD79B mutations are common in leg type, similar to aggressive lymphomas of the brain and testis |
| Inheritance | Not inherited |
4. How does it look?
4.1 On the skin
| Type | What it looks like |
|---|---|
| Marginal zone | Pink to red-purple papules, plaques or nodules, often several, on the arms, shoulders or trunk |
| Follicle centre | A firm, smooth, red or plum-coloured lump or plaque on the scalp, forehead or back, sometimes surrounded by smaller spots or a red patch |
| Leg type | Fast-growing red or bluish-red lumps on one or both lower legs, which may break down into ulcers |
| Surface | Usually smooth and shiny; scaling and itch are uncommon |
| Sensation | Usually painless |
4.2 Under the microscope
| Type | What the pathologist sees |
|---|---|
| Marginal zone | Small B cells and plasma cells around follicles; plasma cells often make a single type of light chain |
| Follicle centre | Medium to large centrocytes in follicles or sheets; BCL6-positive, usually BCL2-negative or weak |
| Leg type | Sheets of large immunoblasts; strongly positive for BCL2, MUM1 and FOXP1; often MYD88 mutation |
4.3 On scans
| Test | What it shows |
|---|---|
| CT or PET-CT | Normal in true primary skin lymphoma; used to make sure there is no lymphoma inside the body |
| PET-CT in leg type | Helps detect lymph node or organ spread |
5. Symptoms
Most people with indolent types have no symptoms other than the skin lesions.
5.1 Skin symptoms
| Symptom | Notes |
|---|---|
| Lumps or plaques | Single or several, slowly growing over months |
| Colour change | Pink, red, purple or plum-coloured skin |
| Ulcers | Mainly in leg type, on the shins or calves |
| Swelling | Leg swelling in leg type |
| New lesions | Lesions may come back in nearby or distant skin after treatment, especially in marginal zone lymphoma |
5.2 General symptoms
| Symptom | Notes |
|---|---|
| Fever, night sweats, weight loss | Rare in indolent types; their presence suggests systemic lymphoma or leg type with spread |
| Swollen lymph nodes | Uncommon at diagnosis; should be checked |
| Tiredness | Usually only in advanced leg type |
5.3 When to see a doctor
See a doctor or dermatologist for a skin lump that:
- Keeps growing over weeks or months
- Is red, purple or plum-coloured and does not settle
- Breaks down into a sore that does not heal
- Appears in a group of new spots
5.4 Conditions that can look similar
Skin lymphoma can be mistaken for more common skin problems, so a biopsy is essential.
| Condition | How it differs |
|---|---|
| Insect bite reaction or cutaneous lymphoid hyperplasia | A harmless build-up of immune cells, often after bites, tattoos or vaccinations; cells are mixed rather than one clone |
| Cysts and lipomas | Feel softer or fluid-filled; do not usually change skin colour |
| Skin infections | Painful, warm and often improve with antibiotics |
| Basal cell carcinoma | Pearly lump with fine blood vessels, often on sun-exposed skin |
| Systemic lymphoma in the skin | Looks the same but has lymphoma inside the body as well; found by staging scans |
| Leukaemia cutis | Skin lumps from leukaemia; blood tests are abnormal |
6. Diagnosis
| Test | Why it is done |
|---|---|
| Skin biopsy | A deep punch or excision biopsy confirms lymphoma and its type, using stains such as CD20, BCL2, BCL6, MUM1 and light chains |
| Gene tests | Clonality testing, and sometimes MYD88 testing, support the diagnosis |
| Full skin and lymph node examination | Looks for other lesions |
| Blood tests | Blood count, LDH and other tests; Borrelia serology in some European centres |
| CT or PET-CT | Rules out lymphoma inside the body; required to call it “primary cutaneous” |
| Bone marrow biopsy | Recommended for leg type; usually not needed for indolent types |
Staging
The ISCL/EORTC TNM system for cutaneous lymphomas other than mycosis fungoides is used.
| Stage | Meaning |
|---|---|
| T1 | A single skin lesion |
| T2 | Several lesions in one body region or two neighbouring regions |
| T3 | Widespread lesions in non-neighbouring regions |
| N / M | Spread to lymph nodes (N) or organs (M) |
7. Treatment
7.1 Marginal zone and follicle centre lymphoma
| Situation | Treatment options | Notes |
|---|---|---|
| One or a few lesions | Local radiotherapy, often low dose (for example 2 x 2 Gy) or about 24 Gy | Control rates over 95% in treated areas |
| Small single lesion | Surgical removal | Simple and effective |
| Several lesions | Steroid injections, intralesional rituximab, strong steroid creams | Good for lesions not suitable for radiotherapy |
| Widespread lesions | Intravenous rituximab | Often given weekly for four doses |
| Few symptoms | Watchful waiting | Reasonable, as treatment does not change survival |
| Borrelia-positive | Antibiotics such as doxycycline | Used in some European cases |
Recurrences in the skin are common, especially in marginal zone lymphoma, but they do not usually mean the disease has become dangerous. They are treated in the same way.
7.2 Diffuse large B-cell lymphoma, leg type
| Treatment | Notes |
|---|---|
| R-CHOP chemoimmunotherapy | Rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone; the standard treatment for most patients |
| Radiotherapy | Added for local lesions, or used alone in frail patients |
| Relapse | Options include lenalidomide, ibrutinib, other chemotherapy, CAR-T cell therapy and trials |
| Older or frail patients | Reduced-dose regimens (R-mini-CHOP) or radiotherapy alone |
8. Side effects of treatment
| Treatment | Possible effects | What helps |
|---|---|---|
| Radiotherapy | Redness, temporary hair loss in the area, dry skin | Moisturisers, sun protection |
| Steroid injections | Skin thinning, dents in the skin | Spacing injections |
| Rituximab | Infusion reactions, infections, hepatitis B reactivation | Premedication, hepatitis B testing |
| R-CHOP | Hair loss, infections, nerve tingling, heart effects | Growth factor injections, heart checks |
9. Outlook
| Type | Approximate 5-year disease-specific survival |
|---|---|
| Marginal zone | Close to 100% |
| Follicle centre | About 95% |
| Leg type | About 50-60%; better outcomes since rituximab was added |
For the two indolent types, the outlook is so good that the main aim of treatment is to control the skin lesions with as little harm as possible. Recurrences in the skin occur in up to half of people, particularly with marginal zone lymphoma, but they rarely affect life expectancy.
Leg type is different. It behaves like diffuse large B-cell lymphoma elsewhere in the body, and early, full treatment gives the best chance of long-term control.
In leg type, having lesions on both legs, many lesions or older age is linked to a poorer outlook.
10. Follow-up and living with PCBCL
| Type | Typical follow-up |
|---|---|
| Indolent types | Skin and lymph node checks every 6-12 months; scans only if new symptoms |
| Leg type | Clinic visits every 3 months for the first 2 years, then less often, with scans if needed |
Many people with indolent types live normal lives. Check your skin regularly and report new lumps or sores early. Rarely, an indolent skin lymphoma spreads to other organs, so new general symptoms should be checked.
Treated areas can stay a little darker or lighter than the surrounding skin. Sun protection helps the skin heal evenly. For lesions on the face or scalp, low-dose radiotherapy usually leaves little or no scarring and only short-lived hair loss.
People with leg type are often older and may have other health problems. Support with mobility, wound care for leg ulcers and help at home can make treatment easier to complete.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is skin lymphoma a skin cancer? | It is a cancer of immune cells that live in the skin, not of skin cells themselves |
| Will it spread inside my body? | Rarely, for marginal zone and follicle centre types. Leg type can spread and needs full treatment |
| Do I need chemotherapy? | Usually not for indolent types. Leg type is normally treated with R-CHOP |
| Is it contagious? | No |
| Why do the lesions keep coming back? | Indolent types often recur in the skin; this is expected and treatable |
12. Questions to ask your care team
- Which type of skin B-cell lymphoma do I have, and has the biopsy been reviewed by a specialist lymphoma pathologist?
- Have scans confirmed that the lymphoma is only in the skin?
- Is treatment needed now, or can we watch and wait?
- Would low-dose radiotherapy or surgery suit my lesions?
- What are the chances of new lesions appearing, and what should I do if they do?
- For leg type: what are the side effects of R-CHOP, and is a clinical trial available?
Resources
- Willemze, R. et al. (2019) ‘The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas’, Blood, 133(16), pp. 1703-1714.
- Senff, N.J. et al. (2007) ‘Reclassification of 300 primary cutaneous B-cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers’, Journal of Clinical Oncology, 25(12), pp. 1581-1587.
- Senff, N.J. et al. (2008) ‘European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas’, Blood, 112(5), pp. 1600-1609.
- Grange, F. et al. (2007) ‘Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases’, Archives of Dermatology, 143(9), pp. 1144-1150.
- Beylot-Barry, M. et al. (2018) ‘A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type’, Journal of Investigative Dermatology, 138(9), pp. 1982-1989.
- Hristov, A.C. et al. (2025) ‘Mycosis fungoides, Sezary syndrome, and cutaneous B-cell lymphomas: 2025 update on diagnosis, risk-stratification, and management’, American Journal of Hematology, 100(9), pp. 1603-1628.
- National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.